Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies
The latest clinical and real-world evidence of chimeric antigen receptor (CAR) T-cell therapy continues to challenge standard treatment paradigms for many hematologic malignancies with limited treatment options. In particular, recently approved CAR T-cell therapies are forging a path towards improvi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2022.13.085 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126541063323648 |
|---|---|
| author | Raphaël Stadelmann Anne Cairoli Caroline Arber |
| author_facet | Raphaël Stadelmann Anne Cairoli Caroline Arber |
| author_sort | Raphaël Stadelmann |
| collection | DOAJ |
| description | The latest clinical and real-world evidence of chimeric antigen receptor (CAR) T-cell therapy continues to challenge standard treatment paradigms for many hematologic malignancies with limited treatment options. In particular, recently approved CAR T-cell therapies are forging a path towards improving patient outcomes and health-related quality of life (HRQoL) in difficult-to-treat relapsed/refractory (R/R) blood cancers such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (B-ALL). Here the latest data on commercially available CAR T-cell therapies are summarized and discussed.
PEER REVIEWED ARTICLE |
| format | Article |
| id | doaj-art-f63b821df1564dd29e2eaf30c99459a3 |
| institution | Kabale University |
| issn | 2673-2106 |
| language | English |
| publishDate | 2022-10-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-f63b821df1564dd29e2eaf30c99459a32024-12-12T17:11:28ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-21062022-10-01133Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic MalignanciesRaphaël StadelmannAnne CairoliCaroline ArberThe latest clinical and real-world evidence of chimeric antigen receptor (CAR) T-cell therapy continues to challenge standard treatment paradigms for many hematologic malignancies with limited treatment options. In particular, recently approved CAR T-cell therapies are forging a path towards improving patient outcomes and health-related quality of life (HRQoL) in difficult-to-treat relapsed/refractory (R/R) blood cancers such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (B-ALL). Here the latest data on commercially available CAR T-cell therapies are summarized and discussed. PEER REVIEWED ARTICLEhttps://doi.org/10.36000/hbT.OH.2022.13.085 |
| spellingShingle | Raphaël Stadelmann Anne Cairoli Caroline Arber Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies healthbook TIMES. Oncology Hematology |
| title | Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies |
| title_full | Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies |
| title_fullStr | Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies |
| title_full_unstemmed | Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies |
| title_short | Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies |
| title_sort | significant progress in car t cell therapy for difficult to treat hematologic malignancies |
| url | https://doi.org/10.36000/hbT.OH.2022.13.085 |
| work_keys_str_mv | AT raphaelstadelmann significantprogressincartcelltherapyfordifficulttotreathematologicmalignancies AT annecairoli significantprogressincartcelltherapyfordifficulttotreathematologicmalignancies AT carolinearber significantprogressincartcelltherapyfordifficulttotreathematologicmalignancies |